An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma

Granulocyte colony stimulating factor alters the phenotype of neuroblastoma cells: implications for disease-free survival of high-risk patients

“…Granulocyte colony stimulating factor (GCSF, CSF3) is often administered in hope of restoring neutrophil levels after myeloablative chemotherapy in these neuroblastoma patients [4]. GCSF is also employed to stimulate leukocytosis just before peripheral blood stem cell collection in high-risk neuroblastoma [5][6][7].…”

A randomised study of prophylactic G‐CSF following MRC UKALL XI intensification regimen in childhood ALL and T‐NHL

“…At the Birmingham Children's Hospital, 14 patients were enrolled from a potential 51 eligible during the study period. Of those not enrolled on the study, 8 declined due to the trauma associated with subcutaneous injections, 3 were unable to give informed consent, 21 were not approached to enter the study, and 5 declined for unspeci®ed reasons.…”

2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients With Cancer

“…Hematopoietic growth factors have been studied as adjunctive therapy to antimicrobial therapy for febrile neutropenic patients in several randomized, controlled trials [144][145][146][147][148][149][150][151][152][153][154][155]. These studies show that G-CSF (filgrastim) or granulocyte-macrophage colony-stimulating factor (sargramostim) used as part of the treatment of febrile neutropenic patients can consistently shorten the duration of neutropenia, but these agents have not consistently and significantly reduced other measures of febrile morbidity, including duration of fever, use of anti-infectives, or costs of management of the febrile neutropenic episode.…”